This drug lost the qualification to hang the net, but it is because of the shortage of raw materials!

[ China Pharmaceutical Network Technology News ] On December 12th, Shanxi Pharmaceutical Machinery Collection Network issued the "Notice on Publicity to Cancel the Qualification of Lepu Pharmaceutical Co., Ltd. Compound Ammonia Capsule Network" (hereinafter referred to as "Notice"), the notice shows that Due to the shortage of raw materials, the compound ammonia capsule of Lepu Pharmaceutical has stopped production. Therefore, the company applied to cancel the network hanging in Shanxi Province and promised to cancel the net connection and supply nationwide.

Multi-site shortage of drug notifications

Shortage drugs refer to drugs that are clinically necessary and cannot be supplied normally for a certain period of time, including drugs with uncertain dosages, low prices, unproductive enterprises, and frequent supply shortages in the region. The industry said that although these drugs account for a small proportion of the total drug use, most of them are national essential drugs. If the supply cannot be guaranteed, it may affect the patient's rescue or treatment effect.

However, since this year, Zhejiang, Liaoning, Guangxi, Ningxia, Shanxi, Yunnan, Guizhou, Hubei and other places have issued notices of shortage of drugs, especially in the field of raw materials, and even the price has doubled. The situation of production suspension.

In fact, in order to solve the problem of drug shortage, various measures have been taken in various parts of China. For example, at the end of October this year, Liaoning was guided by the needs of medical institutions, and established a monitoring and early warning mechanism for shortage of drugs, a linkage guarantee mechanism, timely warning of drug shortages, and effective countermeasures to make the shortage of drugs no longer clinically short-lived.

On November 27th, the current health care committee established a sound shortage of drug monitoring context and grading response system, identified more than 500 shortage drug monitoring sentinels, and sorted out 139 clinically short-stirty drug lists, most of which have resumed production supply. It can be seen that the supply of short-term drugs is also facing some problems and challenges brought about by the failure to implement policies.

The state strikes hard to crack down on monopoly

The shortage of most raw materials is due to environmental high pressure and factory monopoly. It is reported that there are not many raw material drug manufacturers, and there are only one or two manufacturers of some varieties. Once the monopoly is inevitably caught in a shortage situation. In view of the monopoly of raw material medicines, the industry is also not uncommon. The relevant departments have attacked the manufacturers of malicious monopoly raw materials. However, from the overall situation, the current results are not satisfactory.

The author understands that in fact, as early as November 2017, China issued the first "Guidelines on the Price Behavior of Shortage Medicines and APIs Operators", aiming to remind relevant operators not to implement the information on the price increase and the price increase of APIs. Collusion to manipulate market prices and other violations of the Price Law.

The anti-monopoly guidelines were issued, but the local pharmaceutical companies scattered and chaotic, sacrificed the environment for the benefit, malicious goods, these phenomena are not easy to rectify.

In this regard, there is a place for cooperation in the joint opposition to the monopoly of bulk drugs. In September this year, the Zhejiang Pharmaceutical Industry Association and the Qianjiang Evening News drafted a proposal for “Do not say anything about the monopoly of bulk drugs” and submitted it to the members for consideration. After deliberation, 1158 member companies unanimously agreed to participate in the joint initiative - say no to the monopoly of bulk drugs.

At the beginning of December this year, the website of the State Administration of Market Supervision announced that it had issued a tens of thousands of fines for three glacial acetic acid API manufacturers. The news of this huge amount of fine drug raw material monopoly enterprises has caused a sensation in the industry. The industry expects that the supervision and rectification of the raw material drug industry will be more stringent in the future. Under this background, pharmaceutical companies should operate rationally and not harm the pharmaceutical enterprises and patients. , resulting in unfair market competition.